Teva Pharmaceutical Industries Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.41B | $-1.64B | $-559.0M | $-2.45B | $417.0M | $-3.99B | $-999.0M | $-2.15B |
| Depreciation & Amortization | $1.00B | $1.06B | $1.15B | $1.31B | $1.33B | $1.56B | $1.72B | $1.84B |
| Depreciation | $421.0M | $471.0M | $537.0M | $576.0M | $528.0M | $537.0M | $609.0M | $676.0M |
| Amortization | $581.0M | $588.0M | $616.0M | $732.0M | $802.0M | $1.02B | $1.11B | $1.17B |
| Stock-Based Compensation | $157.0M | $123.0M | $121.0M | $124.0M | $119.0M | $129.0M | $119.0M | $155.0M |
| Net Cash from Operating Activities | $1.65B | $1.25B | $1.37B | $1.59B | $798.0M | $1.22B | $748.0M | $2.45B |
| Investing Activities | ||||||||
| Capital Expenditures | $501.0M | $498.0M | $526.0M | $548.0M | $562.0M | $578.0M | $525.0M | $651.0M |
| Business Acquisitions | $0 | $15.0M | $0 | $7.0M | $0 | $0 | — | — |
| Net Cash from Investing Activities | $737.0M | $792.0M | $968.0M | $656.0M | $1.52B | $863.0M | $1.36B | $1.87B |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | $12.0M |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-2.15B | $-1.79B | $-1.91B | $-1.49B | $-2.17B | $-1.89B | $-1.93B | $-3.35B |
| Net Change in Cash | $256.0M | $74.0M | $393.0M | $636.0M | $21.0M | $202.0M | $193.0M | $819.0M |
| Free Cash Flow | $1.15B | $749.0M | $842.0M | $1.04B | $236.0M | $638.0M | $223.0M | $1.80B |